| LEVALBUTEROL HYDROCHLORIDE
Xopenex, Xopenex HFA
Classifications: beta-adrenergic agonist; bronchodilator; Therapeutic: bronchodilator; beta-adrenergic agonist
Pregnancy Category: C
0.63 mg/3 mL, 1.25 mg/3 mL inhalation solution
An isomer of albuterol with beta2-adrenergic agonist properties, drug acts on the beta2 receptors of the smooth muscles of the bronchial tree, thus resulting in bronchodilation.
Effective bronchodilator that decreases airway resistance, facilitates mucous drainage, and increases vital capacity.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease.
Hypersensitivity to levalbuterol or albuterol; angioedema; pregnancy (category C); children <6 y; lactation.
Cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, hypertension, QT elongation, convulsive
disorders; diabetes mellitus, diabetic ketoacidosis; older adults; seizures, status asthmaticus, tachycardia; hypersensitivity
to sympathetic amines; hyperthyroidism, thyrotoxicosis.
Route & Dosage
Adult: Inhalation 0.63 mg by nebulization t.i.d. every 68 h, may increase to 1.25 mg t.i.d. if needed
Child (611 y): Inhalation 0.31 mg by nebulization t.i.d. every 68 h (max: 0.63 mg t.i.d.)
- Use vials within 2 wk of opening pouch. Protect vial from light and use within one wk after removal from pouch. Use only
if solution in vial is colorless.
INCOMPATIBILITIES Solution/additive: Compatibility when mixed with other drugs in a nebulizer has not been established.
- Store at 15°25° C (59°77° F) in protective foil pouch.
Adverse Effects (≥1%)Body as a Whole:
Allergic reactions, flu syndrome, pain. CNS:
Migraine, dizziness, nervousness, tremor, anxiety. CV:
Increased cough, viral infection, rhinitis, sinusitis
, turbinate edema, paradoxical bronchospasm. Endocrine:
Increase in serum glucose.
InteractionsDrug: beta-adrenergic blockers
may antagonize levalbuterol
, tricyclic antidepressants
may potentiate levalbuterol
effects on vascular system; ECG changes or hypokalemia may be exacerbated by loop
or thiazide diuretics
515 min. Duration:
36 h. Half-Life:
Assessment & Drug Effects
- Monitor for S&S of CNS or cardiovascular stimulation (e.g., BP, HR, respiratory status).
- Lab tests: Periodic serum potassium levels especially with coadministered loop or thiazide diuretics.
- Monitor diabetics for loss of glycemic control.
Patient & Family Education
- Seek medical advice immediately if a previously effective dose becomes ineffective.
- Report immediately to physician: chest pains or palpitations, swelling of the eyelids, tongue, lips, or face; increased wheezing
or difficulty breathing.
- Do not use drug more frequently than prescribed.
- Exercise caution with hazardous activities; dizziness and vertigo are possible side effects.
- Check with physician before taking OTC cold medication.